Literature DB >> 25621796

I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

H Yamamoto1, N Uchida2, N Matsuno1, A Kon1, A Nishida1, H Ota1, T Ikebe1, N Nakano1, K Ishiwata1, H Araoka3, S Takagi1, M Tsuji1, Y Asano-Mori1, G Yamamoto1, K Izutsu2, K Masuoka1, A Wake1, A Yoneyama3, S Makino4, S Taniguchi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25621796     DOI： 10.1038/bmt.2014.316

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts.

Authors:  K Theilgaard-Mönch; K Raaschou-Jensen; H Palm; K Schjødt; C Heilmann; L Vindeløv; N Jacobsen; E Dickmeiss
Journal:  Bone Marrow Transplant       Date:  2001-12       Impact factor: 5.483

Review 2.  Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.

Authors:  A J Barrett; B N Savani
Journal:  Leukemia       Date:  2006-07-27       Impact factor: 11.528

3.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Authors:  Boglarka Gyurkocza; Rainer Storb; Barry E Storer; Thomas R Chauncey; Thoralf Lange; Judith A Shizuru; Amelia A Langston; Michael A Pulsipher; Christopher N Bredeson; Richard T Maziarz; Benedetto Bruno; Finn B Petersen; Michael B Maris; Edward Agura; Andrew Yeager; Wolfgang Bethge; Firoozeh Sahebi; Frederick R Appelbaum; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

4.  Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.

Authors:  S El Kourashy; T Williamson; M A Chaudhry; M L Savoie; A R Turner; L Larratt; J Storek; N J Bahlis; C B Brown; M Yang; D Quinlan; M Geddes; N Zacarias; A Daly; P Duggan; D A Stewart; J A Russell
Journal:  Bone Marrow Transplant       Date:  2010-11-08       Impact factor: 5.483

5.  Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.

Authors:  Tsunehiko Komatsu; Hiroto Narimatsu; Ai Yoshimi; Naoki Kurita; Manabu Kusakabe; Akiko Hori; Naoko Murashige; Tomoko Matsumura; Kazuhiko Kobayashi; Koichiro Yuji; Yuji Tanaka; Masahiro Kami
Journal:  Ann Hematol       Date:  2006-10-12       Impact factor: 3.673

6.  Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).

Authors:  P Patel; K Sweiss; S Nimmagadda; W Gao; D Rondelli
Journal:  Bone Marrow Transplant       Date:  2010-12-06       Impact factor: 5.483

7.  Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Authors:  Gheath Alatrash; Marcos de Lima; Nelson Hamerschlak; Matteo Pelosini; Xuemei Wang; Lianchun Xiao; Fabio Kerbauy; Alexandre Chiattone; Gabriela Rondon; Muzaffar H Qazilbash; Sergio A Giralt; Leandro de Padua Silva; Chitra Hosing; Partow Kebriaei; Weiqing Zhang; Yago Nieto; Rima M Saliba; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-18       Impact factor: 5.742

8.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

9.  Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Authors:  Naoyuki Uchida; Atsushi Wake; Shinsuke Takagi; Hisashi Yamamoto; Daisuke Kato; Yoshiko Matsuhashi; Tomoko Matsumura; Sachiko Seo; Naofumi Matsuno; Kazuhiro Masuoka; Eiji Kusumi; Koichiro Yuji; Shigesaburo Miyakoshi; Michio Matsuzaki; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

10.  Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

Authors:  Mitchell E Horwitz; Ashley Morris; Cristina Gasparetto; Keith Sullivan; Gwynn Long; John Chute; David Rizzieri; Jackie McPherson; Nelson Chao
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742
View more
  4 in total

1.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

2.  Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.

Authors:  Takanori Ohta; Yasuhiro Sugio; Hiroshi Imanaga; Seidou Oku; Yuju Ohno
Journal:  Int J Hematol       Date:  2019-06-13       Impact factor: 2.490

Review 3.  Hematopoietic stem cell transplantation for acute myeloid leukemia.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

4.  Examination of a nutritional treatment pathway according to pretreatment health status and stress levels of patients undergoing hematopoietic stem cell transplantation.

Authors:  Takashi Aoyama; Osamu Imataki; Akifumi Notsu; Takashi Yurikusa; Koki Ichimaru; Masanori Tsuji; Kanako Yoshitsugu; Masafumi Fukaya; Terukazu Enami; Takashi Ikeda
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.